Article Text

other Versions

Long-Term Visual and Anatomic Outcomes Following Anti-VEGF Monotherapy for Retinal Angiomatous Proliferation
  1. Tarek S Hemeida1,
  2. Pearse A Keane1,
  3. Laurie Dustin2,
  4. Srinivas R Sadda1,
  5. Amani A Fawzi1,*
  1. 1 Doheny Eye Institute, Department of Ophthalmology, Keck School of Medicine of the USC, United States;
  2. 2 Department of Preventative Medicine, Keck School of Medicine of the USC, United States
  1. Correspondence to: Amani A Fawzi, Ophthalmology, Doheny Retina Institute, United States, 1450 San Pablo Street, LA, 90033, United States; afawzi{at}


Purpose: To study the long-term visual and anatomic outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy for the treatment of patients with retinal angiomatous proliferation (RAP).

Methods: Retrospective review of patients who were diagnosed with AMD and RAP lesions, and who received anti-VEGF injections as the only mode of therapy.

Results: 20 eyes (15 patients; 9 women, 6 men) with RAP lesions treated by anti- VEGF were encountered. Mean patient age was 85.8 years (SD ± 4.54). Nine eyes were treated with intravitreal ranibizumab alone, 8 eyes with bevacizumab alone, and 3 eyes received both drugs. At the 1, 3 and 6 month follow-up the median VA had improved from baseline (20/72) to 20/52, (range: 20/25 to 20/400), 20/45 (range: 20/20 to 20/400), and 20/56 (range: 20/20 to 20/400), respectively, (P> 0.001, P= 0.001, and P= 0.05, respectively). At 24 month follow-up, the improvement of VA, defined as halving of the visual angle, occurred in 37.5% of the cases.

Conclusions: Anti-VEGF monotherapy represents a useful treatment option for RAP, with stable or improved visual acuity in 62.5% of patients at 2 years. Although 25% of eyes only required a single injection, in most cases (75%) repeated treatments were required, therefore long-term follow-up is recommended.

Statistics from


    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • At a glance
      Harminder S Dua Arun D Singh
    • Review
      Bhaskar Gupta Sreedhar Jyothi Sobha Sivaprasad